Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by Synchronouson Aug 16, 2010 8:44pm
280 Views
Post# 17355463

RE: RE: RE: RE: +4.6 Million in Q2?

RE: RE: RE: RE: +4.6 Million in Q2?s'ok grumpy ...terry is right ... he replied like an egomanic....  but hes right.
Note how I had a question mark on my first statement?

I shouldnt have done a quicky post using the head liner numbers in rough math.
Too much showing up on books this quarter to just breeze over the highlights.

anyway...  $11.4 M profit is coming from subtracting all the book keeping numbers from the $19.7M quarter loss.

looks like LRR ended up having $15M cash leftover .. which got pushed against the debt.... good.

Though how will the future repayment rate will look ?

....
General and administrative expenses 3,681
Did that include the severence packages?

Either way looking like decent financial footing.
What was the market expecting? ... why the drop?


Bullboard Posts